Opendata, web and dolomites

REAP SIGNED

Repair of DNA lesions induced by platinum drugs

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 REAP project word cloud

Explore the words cloud of the REAP project. It provides you a very rough idea of what is the project "REAP" about.

deficient    gg    outcomes    difference    global    data    unreported    novelty    patient    differential    validation    benefit    cytotoxicity    cells    resistance    striking    dna    ddr    pilot    ambition    characterization    experimental    lesions    genes    patients    commitment    transfer    versus    genome    drugs    observations    techniques    ner    host    experts    damage    extrapolate    multiple    regulate    followed    differently    treat    sensitive    identification    knockout    excision    considerable    shown    performing    multidisciplinary    cas9    cancer    bulky    union    tumor    half    scientific    follows    nucleotide    screens    functional    cisplatin    tumors    molecular    genetic    vital    efficient    platinum    chemotherapy    unable    principles    mutated    potentially    repair    recognition    backgrounds    tissues    treatment    unbiased    unrecognized    schemes    oxaliplatin    insensitive    understand    nonmalignant    translational    crispr    inducing    expressed    receiving    validated   

Project "REAP" data sheet

The following table provides information about the project.

Coordinator
CEMM - FORSCHUNGSZENTRUM FUER MOLEKULARE MEDIZIN GMBH 

Organization address
address: LAZARETTGASSE 14 AKH BT 25.3
city: WIEN
postcode: 1090
website: http://www.oeaw.ac.at/

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Austria [AT]
 Total cost 186˙167 €
 EC max contribution 186˙167 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2018
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2019
 Duration (year-month-day) from 2019-05-01   to  2021-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CEMM - FORSCHUNGSZENTRUM FUER MOLEKULARE MEDIZIN GMBH AT (WIEN) coordinator 186˙167.00

Map

 Project objective

DNA damage-inducing platinum drugs, such as oxaliplatin and cisplatin, are used to treat about half of all patients receiving chemotherapy. Although potentially very efficient, many patients develop resistance for yet unrecognized reasons. Better understanding of the DNA damage response (DDR) to platinum-DNA lesions is therefore much needed for improving treatment outcomes. By performing DDR-dedicated CRISPR/Cas9 knockout screens, the applicant has shown that some cancer cells deficient in the major repair of bulky DNA lesions, global-genome nucleotide excision repair (GG-NER), are insensitive to oxaliplatin but sensitive to cisplatin. This striking difference remains as of yet unreported, but might explain differential responses of tumors to drugs. The aim of this proposal is to understand why GG-NER is unable to repair oxaliplatin lesions in particular genetic backgrounds. To do so, unbiased identification of genes differently mutated or expressed in oxaliplatin-sensitive versus insensitive cells will be followed by validation and in-depth functional characterization of identified targets. The ambition is to extrapolate experimental observations to translational knowledge. Validated targets will be studied in patient-derived tumor tissues as compared to nonmalignant tissues and related to patients’ treatment responses. Identification of genetic factors that regulate platinum lesions recognition by GG-NER will contribute to the understanding of molecular principles of platinum drugs cytotoxicity and might thus have considerable benefit on current cancer treatment schemes. The novelty of the pilot data, the unique multidisciplinary design of the project, the use of state-of-the-art molecular techniques and a collaboration with multiple European experts will ensure high scientific impact. Both, the applicant and the host will greatly benefit from the vital knowledge transfer. This project follows the European Union's commitment to cancer research.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "REAP" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "REAP" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

NaWaTL (2020)

Narrative, Writing, and the Teotihuacan Language: Exploring Language History Through Phylogenetics, Epigraphy and Iconography

Read More  

SIMIS (2020)

Strongly Interacting Mass Imbalanced Superfluid with ultracold fermions

Read More  

iRhomADAM (2020)

Uncovering the role of the iRhom2-ADAM17 interaction in inflammatory signalling

Read More